<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55006403"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<docTitle>
	<reference>BIOPHARMACEUTICS &amp; DRUG DISPOSITION<lb/></reference>
	</docTitle>

	<reference>Biopharm. Drug Dispos. 19: 159 – 162 (1998)<lb/></reference>

	<docTitle>
	<titlePart>Dose-Proportional Pharmacokinetics of a New 5-Lipoxygenase<lb/> Inhibitor, ABT-761, in Healthy Volunteers<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Shekman L. Wong*, Jeffrey Drajesk, Min S. Chang, Galen Witt and Walid M. Awni<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Abbott Laboratories,</affiliation>
	</byline>

	<address>100 Abbott Park Road, Abbott Park, Abbott Park, IL 60064-3500, USA<lb/></address>

	<div type="abstract">ABSTRACT: ABT-761, a new potent 5-lipoxygenase inhibitor, is under development for the treatment of<lb/> asthma. The pharmacokinetics and dose proportionality of ABT-761 after single doses (10 – 160 mg) of<lb/> ABT-761 in 24 healthy male volunteers were investigated in a double-blind, placebo-controlled study. The<lb/> compound was well tolerated, with no clinically significant effects on vital sign measurements, hemato-<lb/>logical parameters, clinical chemistry, urinalysis, or electrocardiogram. The plasma concentration– time<lb/> profile of ABT-761 indicates that the drug declines in a monoexponential fashion after moderately slow<lb/> absorption, with a t max value of approximately 4 h. The terminal elimination t 1/2 averaged 15 h, and was<lb/> dose independent. ABT-761 mean values of C max and AUC were linearly related to drug dose. ABT-761 is<lb/> well tolerated in healthy volunteers and the pharmacokinetics are linear in the single-dose range between<lb/> 10 and 160 mg.</div>

	<note type="copyright">© 1998 John Wiley &amp; Sons, Ltd.<lb/></note>

	<keyword>Key words: 5-lipoxygenase; pharmacokinetics; asthma<lb/></keyword>

		</front>
	</text>
</tei>
